Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751298 | 0.85 | HCAR2 (0.48) | HCAR2 | |
| SCHEMBL28835650 | 0.74 | HCAR2 (0.49) | L3MBTL1KDM4EALPLPOLBHCAR2 | |
| SCHEMBL5751439 | 0.71 | L3MBTL1 (0.41) | L3MBTL1KDM4EALOX12TUBB4ATUBB | |
| SCHEMBL3584758 | 0.71 | CYP1A2 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9025212 | 0.71 | HCAR2 (0.66) | L3MBTL1KDM4EPOLBHCAR2 | |
| SCHEMBL14471302 | 0.70 | L3MBTL1 (0.49) | L3MBTL1KDM4EALPLPOLBKDM5B | |
| SCHEMBL3955623 | 0.68 | HCAR2 (0.65) | KDM4EPOLBHCAR2 | |
| SCHEMBL14471313 | 0.67 | L3MBTL1 (0.48) | L3MBTL1KDM4EALPLPOLBKDM5B | |
| SCHEMBL2869702 | 0.66 | KDM4E (0.46) | L3MBTL1KDM4EALPLPOLBHCAR2 | |
| SCHEMBL10262737 | 0.65 | KDM4E (0.66) | KDM4EALPLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141585-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | claimed |
| EP-1299361-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2006-07-19 | — | — | EP | claimed |
| US-20040209862-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-10-21 | — | — | US | claimed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | claimed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | claimed |
| WO-2002004424-A9 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2002-12-12 | — | — | WO | claimed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | claimed |
| US-7141585-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1299361-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-20040209862-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | disclosed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032184-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | L3MBTL1 3119/4885KDM4E 2314/4885ALPL 3157/4885 |
| US-20040209862-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | L3MBTL1 3119/4885KDM4E 2314/4885ALPL 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.